Evidence summary
The clinical plan combines adverse-event surveillance with assays for reaction products and hematologic markers.
What clinical changes are monitored
The study protocol records local pain, bleeding, infection and other adverse events after each study session. Events are classified by severity and their relationship to study treatment. Scheduled follow-up includes vital signs, the condition of the treated site, and relevant laboratory assessments.
Why reaction products are measured
The Investigator’s Brochure describes the rapid reaction observed when chlorine dioxide contacts blood or tissue in experiments. In the first six Phase 1 safety lead-in participants, the protocol collects timed blood samples before and after the initial session to measure changes in plasma chlorite, chlorate and chloride.
Blood and organ-function measures
The protocol monitors hemoglobin, methemoglobin and markers associated with red blood cell breakdown, including lactate dehydrogenase, bilirubin and haptoglobin. Kidney function, electrolytes and uric acid help characterize organ function and biochemical changes associated with tumor breakdown. These measures are evaluated alongside the clinical observations.
